Q3 EPS Estimates for Gossamer Bio Lowered by Leerink Partnrs

Key Points

• Analysts at Leerink Partners have reduced their Q3 2025 earnings per share (EPS) estimates for Gossamer Bio from ($0.21) to ($0.22).
• Goldman Sachs has raised their target price for Gossamer Bio from $7.00 to $8.00, maintaining a "buy" rating, while Wedbush has increased their price objective from $4.00 to $5.00.
• Institutional investors control approximately 81.23% of Gossamer Bio's stock, indicating significant institutional interest in the company.

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Leerink Partnrs lowered their Q3 2025 EPS estimates for Gossamer Bio in a report issued on Wednesday, August 6th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.22) for the quarter, down from their prior estimate of ($0.21). The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share. Leerink Partnrs also issued estimates for Gossamer Bio's FY2025 earnings at ($0.77) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at ($0.78) EPS.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The firm had revenue of $11.49 million for the quarter, compared to analyst estimates of $4.12 million.

Other equities analysts have also issued reports about the stock. Wall Street Zen lowered shares of Gossamer Bio from a "hold" rating to a "sell" rating in a report on Saturday. The Goldman Sachs Group raised their target price on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a report on Friday, May 16th. Scotiabank began coverage on shares of Gossamer Bio in a report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 target price on the stock. Finally, Wedbush raised their price target on shares of Gossamer Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $8.50.

Gossamer Bio Price Performance

GOSS stock traded up $0.02 during mid-day trading on Friday, hitting $1.76. The stock had a trading volume of 3,069,886 shares, compared to its average volume of 3,500,859. The company has a current ratio of 4.40, a quick ratio of 5.71 and a debt-to-equity ratio of 6.70. Gossamer Bio has a 52 week low of $0.66 and a 52 week high of $2.23. The firm has a market capitalization of $400.19 million, a P/E ratio of -2.84 and a beta of 1.96. The firm has a fifty day simple moving average of $1.51 and a 200 day simple moving average of $1.24.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at approximately $121,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at approximately $53,000. Geode Capital Management LLC boosted its stake in shares of Gossamer Bio by 100.4% in the 2nd quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company's stock valued at $5,604,000 after purchasing an additional 2,282,632 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at approximately $48,000. Finally, Acadian Asset Management LLC boosted its position in Gossamer Bio by 12.4% during the 2nd quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company's stock worth $8,786,000 after buying an additional 787,909 shares during the period. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.